AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-22 (cancelled)

Claim 23 (currently amended): A method for treating an adult patient suffering from severe systemic inflammatory response syndrome, comprising:

administering to said patient an effective amount of a composition comprising at least one molecule containing selenium, wherein said effective amount is a daily dose of a selenium composition containing about 0.025 to 1 mg/kg of bodyweight of atomic selenium.

Claim 24 (previously added): The method according to claim 23, wherein said patient is treated for a severe systemic inflammatory response selected from the group consisting of peritonitis, pneumopathies, meningitis and bacterial septicemias in a septic shock state.

Claim 25 (cancelled)

Claim 26 (previously added): The method according to claim 23, wherein said patient is treated for a severe systemic inflammatory response selected from the group consisting of

bacterial infections, parasitic infections, fungal infections, viral infections and rheumatoid polyarthtritis.

Claim 27 (cancelled)

Claim 28 (previously added): The method according to claim 23, wherein said selenium is in the form of sodium selenite.

Claim 29 (previously amended): The method according to claim 23, wherein several molecules containing selenium are used.

Claim 30 (previously added): The method according to claim 23, wherein said selenium is in a form selected from the group consisting of selenite, selenate, selenocysteine, selenomethionine, selenodiglutathione, selenomethyl selenocysteine, dimethyl selenoxide, selenocystamine, selenated yeasts, synthetic chemicals containing one or more atoms of selenium and sodium selenite.

Claim 31 (previously added): The method according to claim 23, wherein said selenium is administered by a parenteral route, intraperitoneal route or oral route.

Claim 32 (previously added): The method according to claim 23, wherein said composition further comprises a non-selenium compound which inhibits an oxidative metabolism or inflammatory reaction.

Claim 33 (previously added): The method according to claim 32, wherein said associated non-selenium compound is selected from the group consisting of vitamin E, vitamin C, a glutathione precursor, an iron chelator, a copper chelator, copper and zinc.

Claim 34 (previously added): The method according to claim 32, wherein said composition further comprises gold to inhibit an inflammatory reaction.

Claim 35 (currently amended): A method for treating a patient suffering from severe systemic inflammatory response syndrome or any state corresponding to a severe acute attack of an inflammatory pathology causing an exacerbation of cytokine secretion, comprising:

administering in a first treatment to said patient an effective amount of at least one molecule containing selenium, wherein said effective amount is a daily dose of a selenium composition containing about 0.025 to 1 mg/kg of bodyweight of atomic selenium,

followed by further administering to said patient a subsequent treatment of an effective amount of at least one molecule containing selenium, wherein said effective amount in said second treatment is a daily dose of a selenium composition containing about 0.00625 to 0.025 mg/kg of atomic selenium.

Claim 36 (previously added): The method according to claim 35, wherein said patient is treated for a severe systemic inflammatory response selected from the group consisting of peritonitis, pneumopathies, meningitis and bacterial septicemias in a septic shock state.

Claim 37 (cancelled)

Claim 38 (previously added): The method according to claim 35, wherein said patient is treated from a severe systemic inflammatory response selected from the group consisting of bacterial infections, parasitic infections, fungal infections, viral infections and rheumatoid polyarthtritis.

Claim 39 (cancelled)

Claim 40 (previously amended): The method according to claim 35, wherein

said first treatment is administered during a time period between a first day to fourth day of the method, and

said subsequent treatment is administered 1 to 20 days after said first treatment.

Claims 41-43 (cancelled)

Claim 44 (new): A method for treating an adult patient suffering from severe systemic inflammatory response syndrome comprising:

- administering to said patient an effective amount of a composition comprising at least one molecule containing

selenium, wherein said effective amount is a daily dose of selenium composition providing about 2 to 80 mg of atomic selenium.